“Buy” was Kept on Global Blood Therapeutics (GBT) by Nomura; with $109 Target.

June 29, 2018 - By Don Salinas

Global Blood Therapeutics, Inc. (NASDAQ:GBT) Corporate Logo

Reiterated Global Blood Therapeutics (GBT) Rating.

Nomura have a $109 target price per share on Global Blood Therapeutics (GBT) shares. On Thursday, 28 June the $2.40B market cap company have “Buy” stock rating. This target price per share gives a potential 135.17 % upside on the stock.

Global Blood Therapeutics, Inc. (NASDAQ:GBT) Ratings Coverage

A total of 10 analysts rate Global Blood Therapeutics (GBT) as follows: 9 “Buy”, 1 “Hold” and 0 “Sell”. Тherefore 90% are bullish. (GBT) has 25 ratings reports on Jun 29, 2018 according to StockzIntelligence. On Tuesday, March 6 the firm has “Overweight” rating given by Morgan Stanley. On Tuesday, March 20 the stock of Global Blood Therapeutics, Inc. (NASDAQ:GBT) has “Buy” rating given by Oppenheimer. On Thursday, January 11 the rating was maintained by Oppenheimer with “Buy”. On Monday, March 12 H.C. Wainwright maintained the shares of GBT in report with “Buy” rating. On Wednesday, February 28 the firm has “Buy” rating given by H.C. Wainwright. On Thursday, January 11 the rating was maintained by H.C. Wainwright with “Buy”. In Tuesday, May 8 report SunTrust maintained the stock with “Buy” rating. The company rating was maintained by Wedbush on Monday, May 21. On Thursday, January 11 the firm has “Buy” rating given by Cowen & Co. On Wednesday, June 27 the firm earned “Buy” rating by Cantor Fitzgerald.

GBT is hitting $46.35 during the last trading session, after decreased 2.32%.Global Blood Therapeutics, Inc. has volume of 751,216 shares. Since June 29, 2017 GBT has risen 60.31% and is uptrending. GBT outperformed by 47.74% the S&P500.

On August, 6. Investors expect Global Blood Therapeutics, Inc. (NASDAQ:GBT) to publish its quarterly earnings, as reported by Faxor. Analysts predict $-0.87 EPS. That’s $0.32 down or 58.18 % from 2017’s earnings of $-0.55. Last quarter $-0.87 EPS was reported. Analysts sees 0.00 % EPS growth this quarter.

Global Blood Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics to treat grievous blood disorders.The company has $2.40 billion market cap. The Company’s lead product candidate is voxelotor, an oral once-daily therapy that modulates hemoglobin's affinity for oxygen, which is in Phase III clinical trials in adult and adolescent patients with sickle cell disease .Currently it has negative earnings. The firm is also involved in evaluating the safety and pharmacokinetics of single and multiple doses of voxelotor in a Phase IIa clinical trials of adolescent and pediatric patients with SCD; and other research and development activities that are in pre-clinical phase.

For more Global Blood Therapeutics, Inc. (NASDAQ:GBT) news posted recently go to: Nasdaq.com, Benzinga.com, Seekingalpha.com, Seekingalpha.com or Nasdaq.com. The titles are as follows: “GBT Announces Positive Top-line Data from Part A of the Phase 3 HOPE Study of Voxelotor in Sickle Cell Disease” posted on June 27, 2018, “Global Blood Therapeutics Meets Primary Endpoints In Sickle Cell Study, Seeks Accelerated FDA Approval” on June 27, 2018, “GBT’s voxelotor shows lower treatment effect in adolescents with SCD in mid-stage study; shares slip 4% premarket” with a publish date: June 15, 2018, “Rounds Report: Global Blood Therapeutics Made A Strong Run Due To The Positive Clinical Binary” and the last “GBT Announces Upcoming Data Presentations Supporting Voxelotor Sickle Cell Disease (SCD) Program at …” with publication date: June 08, 2018.

Global Blood Therapeutics, Inc. (NASDAQ:GBT) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.